influenzae rd kw20 (ATCC)
Structured Review

Influenzae Rd Kw20, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 153 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/influenzae rd kw20/product/ATCC
Average 95 stars, based on 153 article reviews
Images
1) Product Images from "Evolution of beta-lactam resistance causes fitness reductions and several cases of collateral sensitivities in the human pathogen Haemophilus influenzae"
Article Title: Evolution of beta-lactam resistance causes fitness reductions and several cases of collateral sensitivities in the human pathogen Haemophilus influenzae
Journal: Antimicrobial Agents and Chemotherapy
doi: 10.1128/aac.00576-25
Figure Legend Snippet: Increasing number of mutations and changes in beta-lactam minimum inhibitory concentrations (MICs) in six evolution experiments. Number of mutations (black) and minimum inhibitory concentration fold increase compared to the parental strain Rd KW20 for ampicillin (Amp, red), cefotaxime (Ctx, green), and ceftriaxone (Cro, blue) in selected clones over 20 passages (two or five clones per passage). Bacterial population ( A ) without antibiotic exposure and exposed to increasing concentrations of ( B ) ampicillin, ( C ) cefotaxime, ( D ) ceftriaxone replicate 1, ( E ) ceftriaxone replicate 2, and ( F ) ceftriaxone replicate 3. Shaded areas represent the 95% confidence interval.
Techniques Used: Concentration Assay, Clone Assay
Figure Legend Snippet: Maximum likelihood phylogeny of H. influenzae Rd KW20 clones evolved in the presence of ampicillin ( A , 53 clones), cefotaxime ( B , 56 clones), and ceftriaxone ( C , 57 clones). Amino acid substitutions in the penicillin-binding protein 3 (PBP3) and presence of mutations in specified genes as well as minimum inhibitory concentration (MIC) changes over time are color coded. Strains that exceeded the clinical breakpoint for ampicillin/cefotaxime/ceftriaxone according to EUCAST breakpoints are marked with a white star at the MIC heatmap. The specified genes are those in which at least 20 clones from the whole set of selected clones exhibited mutations but did not mutate under antibiotic-free conditions.
Techniques Used: Clone Assay, Binding Assay, Concentration Assay
Figure Legend Snippet: Crystal structure of transpeptidase domain (residues 254–610) of the penicillin-binding protein 3 (PBP3) of H. influenzae with superimposed ampicillin ( A , colored in cyan) and cefotaxime ( B , magenta) molecules. In vitro selected amino acid substitutions in PBP3 Thr332lle, Thr443Ala, Ala530Ser, Asp551Tyr, and Ala561Glu are in red. Known positions for amino acid substitutions defining established PBP3 resistance groups are in green.
Techniques Used: Binding Assay, In Vitro
Figure Legend Snippet: Bacterial fitness of selected clones derived from evolving populations exposed to ampicillin (Amp), cefotaxime (Ctx), and ceftriaxone (Cro). Bacterial fitness measured as relative growth difference between the ancestral strain ( H. influenzae Rd KW20) and the selected clone. A relative fitness of 1 indicates no fitness cost, whereas a value greater or less than 1 indicates increased or decreased fitness, respectively. The black bars represent standard deviations. * P adj < 0.05, ** P adj < 0.01, *** P adj < 0.001. The heatmap indicates MIC values of Amp, Ctx, and Cro (in mg/L) of the respective strain (already presented in ). Stars indicate clinical resistance above the respective EUCAST breakpoints. Hatched panels indicate phenotypic heterogeneity. Clones that were derived from the same evolution experiment are grouped together on the y -axis.
Techniques Used: Clone Assay, Derivative Assay
Figure Legend Snippet: Collateral effects of increased MICs against individual beta-lactam antibiotics. Heat map of log 2 -transformed relative increase in MIC of ampicillin, cefotaxime, ceftriaxone (underlying MIC values already presented in ), meropenem (beta-lactams), amikacin, kanamycin, gentamicin (aminoglycosides), levofloxacin, moxifloxacin (fluoroquinolones), clarithromycin (macrolide), vancomycin (glycopeptide), rifampicin (ansamycin), colistin (polymyxin), and tetracycline (tetracycline) in mutant clones relative to the MIC of the parental strain H. influenzae Rd KW20. Selected clones were evolved in the multi-step evolution experiment. Stars indicate clinical resistance above the respective EUCAST breakpoints (not available for aminoglycosides, clarithromycin, vancomycin, and colistin). Hatched panels indicate phenotypic heterogeneity. Clones that were derived from the same evolution experiment are grouped together on the y -axis.
Techniques Used: Transformation Assay, Glycoproteomics, Mutagenesis, Clone Assay, Derivative Assay